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OR (95%CI) P value
7.15 (5.09—10.03) 0.000
0.75 (0.59—0.96) 0.013
5.49 (2.38—12.64) 0.000
0.54 (0.40—0.72) 0.000
1.32 (1.05—1.66) 0.008
1.94 (1.36—2.76) 0.000
1.65 (1.22—2.23) 0.000
1.90 (1.22—2.96) 0.002
OR (95%CI) P value
5.88 (2.26—15.28) 0.000
0.41 (0.18—0.88) 0.016
1.99 (1.38—2.89) 0.000
1.60 (1.09—2.36) 0.010
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diagnosis of and surveillance for hepatitis E would require
the use of anti-HEV IgM assays with the better performance
characteristics.
doi:10.1016/j.ijid.2010.02.202014th International Congress on Infectious Diseases (ICID) Abs
Associated factor
Male couple Anti-HBc positivity
Sex during menstruation
Male couple history of sex with other men
Being younger than 19 years
Sexual initiation before age 15 years
Male couple with more than 10 sex partners lifetime
Male couple with at least 1 more sex partner in last 12 months
Male couple with more than 20 sex partners lifetime
Anti-HBc positivity in men was associated to:
Associated factor
History of sex with other men lifetime
Being younger than 19 years
Sexual initiation before age 15 years
Having sex with women presenting vaginal secretion
Conclusion: Hepatitis B is hyperendemic in Amazonian
indigenous populations studied. These results suggest sex-
ual transmission as the main infection route of Hepatitis B in
indigenous population in reproductive age. A national plan of
Hepatitis B prevention and control in the Amazonian indige-
nous population in Peru is urgently needed to provide proper
education, vaccination and treatment.
doi:10.1016/j.ijid.2010.02.2019
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Background: The routine use of a reliable assay to iden-
tify infection by hepatitis E virus (HEV) belonging to all
4 genotypes is desirable in clinical practice and disease
surveillance. We evaluated assays developed to detect anti-
HEV IgM by interrogating them with panels of specimens
derived from patients known to be infected with HEV belong-
ing to each speciﬁc genotype.
Methods: Two in-house assays (assigned I and II) and
4 commercial assays (III to VI) were evaluated. Assay I
used as antigen a 56-kD protein expressed from open
reading frame (ORF) 2 of the SAR55 HEV strain in a bac-
ulovirus system. Assay II used as antigens recombinant
proteins (each 166 amino acids in length) derived from
ORF2 of 4 HEV strains, each strain originating from apeciﬁc genotype. The commercial assays evaluated were
urchased from International Immuno-Diagnostics (USA),
P-Diagnostics (Singapore), Diagnostic Systems (Russia) and
ikrogen Diagnostik (Germany). All 6 assays were of indirect
sandwich) format. A total of 194 sera comprised the test
anels. The acute hepatitis E panel comprised 51 samples
15 from patients infected by HEV belonging to genotype
, 4 to genotype 2, 15 to genotype 3 and 17 to genotype
). The non-acute hepatitis E panel comprised 143 sam-
les originating from patients with acute hepatitis A, acute
epatitis B and acute hepatitis C, as well as those conva-
escing from acute hepatitis E. Sensitivity, speciﬁcity and
nter-assay agreement were determined.
Results: The sensitivity of the assays among patients
nfected with 4 HEV genotypes varied from 72% for Assay IV
o 98% for Assays I, II and V. The speciﬁcity ranged between
5% for Assay I and 92% for Assays V and VI. Kappa values for
nter-assay agreement ranged from 0.38 to 0.75.
Conclusion: The sensitivities and speciﬁcities of the 6
nti-HEV IgM assays varied substantially. Inter-assay agree-
ents were mostly poor. Precise and accurate laboratory
